MeiraGTx entered into a financing agreement with Oberland Capital Management that could provide the clinical-stage genetic medicines company with up to $400 million to support the advancement and potential commercialization of its late-stage pipeline.

The agreement includes up to $375 million in non-dilutive royalty financing and up to $25 million in equity investment. According to the company, the structure is designed to provide capital while preserving strategic flexibility as it advances programs for X-linked retinitis pigmentosa (XLRP) and radiation-induced xerostomia.

Following regulatory approval, Oberland Capital would receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4.

"The size and terms of Oberland Capital's investment demonstrate exceptional confidence in the strength of the data for these programs to date as well as the large commercial potential for both bota-vec and AAV2-hAQP1," said Alexandria Forbes, PhD, president and CEO of MeiraGTx.

Dr. Forbes said the financing structure leverages the company's multiple late-stage assets to secure "substantial non-dilutive capital while preserving business development flexibility in all aspects of the company."

The agreement also provides access to several milestone-based funding tranches at the company's option:

  • $50 million following positive Phase 2 AQUAx2 data for AAV2-hAQP1, expected in 2027.
  • $50 million upon regulatory approval of bota-vec, anticipated in 2027.
  • $50 million upon regulatory approval of AAV2-hAQP1, anticipated in 2028.

In addition, up to $100 million could become available by mutual agreement to support future products or business development initiatives. Oberland Capital also retains the option to purchase an additional $15 million of MeiraGTx equity.

"MeiraGTx is in the rare position of having three potentially approvable therapies within the next 12 to 24 months, two of which have significant commercial potential," said Michael Bloom, partner at Oberland Capital. "Each of these would be first to market in areas of complete unmet need where there are a large number of patients waiting for these potential treatments."